Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Pentagon vows to keep weapons moving to Ukraine as Kyiv faces a renewed assault by Russia
National Guard delays Alaska staffing changes that threatened national security, civilian rescues
Video of 2 bear cubs pulled from trees prompts North Carolina wildlife investigation but no charges
Nelly Korda 1 shot back through 36 holes at Chevron Championship as she chases 5th straight victory
Candice Swanepoel stuns in a form
Experts on Taylor Swift’s poetry in ‘The Tortured Poets Department'
'Bluey' hits the mark with children and adults alike
Debate over tight end value hovers over Brock Bowers' draft prospects
A warrant for Netanyahu’s arrest was requested. But no decision was made about whether to issue it
Worker electrocuted while doing maintenance on utility pole in upstate New York